ClinicalTrials.gg

Program

cefepime-zidebactam

Also written as “WCK 5222”, “Cefepime-Zidebactam” and “Cefepime-zidebactam (FEP-ZID)”.

Its studies are mostly in Pneumonia, Bacterial · Pyelonephritis · Renal Insufficiency, led by Wockhardt.

Furthest: phase 3, since Jul 5, 20214 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wockhardt41 open or runningphase 3since Jul 5, 2021Oct 20, 2016Dec 31, 2027phase 3 · NCT07885891

Also a collaborator on its studies: medpace-inc and clinartis.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2016First study: phase 1 study in Renal InsufficiencyFirst studyNCT02942810 · 48 enrolled · United States
  2. May 16, 2018Phase 1 study in QT/QTc Interval in Healthy VolunteersNCT03554304 · 60 enrolled · United States
  3. Jul 5, 2021Phase 3 study in Complicated Urinary Tract InfectionNCT04979806 · 530 enrolled · United States, Bulgaria, China and more
  4. Sep 21, 2026Phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)NCT07885891 · 324 planned · Bosnia and Herzegovina, Bulgaria, Croatia and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)NCT07885891

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07885891Hospital Acquired Bacterial Pneumonia (HABP) · Bosnia and Herzegovina, Bulgaria, Croatia and more3Not yet recruitingDec 31, 2027324
NCT04979806Complicated Urinary Tract Infection · United States, Bulgaria, China and more3CompletedNov 25, 2024530
NCT03554304QT/QTc Interval in Healthy Volunteers · United States1CompletedJun 5, 201760
NCT02942810Renal Insufficiency · United States1CompletedApr 201748

How it is read

Names in the registry

  • “WCK 5222”, 2 entries
  • “Cefepime-Zidebactam”, 1 entry
  • “Cefepime-zidebactam (FEP-ZID)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.